Original Article

The Absence of Hepatitis C Virus Infection Among Patients with Hepatitis B virus in Mashhad, Iran

Rostami S\(^1\), Shakeri MT\(^2\), Ghayour-Mobarhan M\(^3\), Nomani H\(^4\), Sepahi S\(^5\), Gerayli S\(^1\), Foghanian B\(^4\), Sadat-Nabavinia M\(^6\), Ahadi M\(^7\), Meshkat Z\(^8\)*

1. Department of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran.
2. Department of Biostatistics, Public Health School, Mashhad University of Medical Sciences, Mashhad, Iran.
3. Biochemistry of Nutritional Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4. Microbiology and Virology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
5. Department of Chemistry, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran.
6. Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
7. Department of Internal Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
8. Women’s Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Background and Aims: Many studies have provided evidence for the role of hepatitis B and C viruses in the development of liver cancer. Although the routine treatment is available for both conditions, no definite guideline is available to treat patients dually infected with HBV and HCV. This study was performed to determine the frequency of HBV/HCV-coinfection in Mashhad, North-East of Iran.

Materials and Methods: In our previous study, 3198 participants were chosen for study of HBV infection from March 2010 to November 2011 in Mashhad, Iran. ELISA method was used to determine the existence of anti-HCV antibody among HBV infected cases.

Results: Of 34 HBsAg positive participants that included equal number of men and women (17 subjects of each gender) with the mean age of 49.9 years, none were positive for anti-HCV antibody.

Conclusion: According to the current study, it could be concluded that the prevalence of HBV/HCV coinfection is low in Mashhad. However, since occult HBV infection may go unnoticed by conventional HBsAg testing, high sensitive molecular techniques are required to investigate the presence of dual infection.

Keywords: Co-infection; hepatitis B virus; hepatitis C virus; Mashhad; Iran

Introduction

Worldwide, a substantial proportion of liver diseases are caused by Hepatitis B virus (HBV) and Hepatitis C virus (HCV). According to The World Health Organization (WHO) figures, an estimated 170 million and 350 million individuals are chronic carriers of HCV and HBV, respectively (1). Patients coinfected with hepatitis B virus (HBV) and hepatitis C virus (HCV), similar to HIV/HCV and HIV/HBV coinfected individuals, are more likely to develop severe hepatic diseases (2-3). Mortality rate is higher among HBV/HCV-coinfected individuals (7.1%) compared to HCV and HBV monoinfected individuals with 3.2% and 5.3%, respectively (4). Compared to patients with HBV and HCV coinfection,
No Evidence of Hepatitis C Virus among Patients …

patients monoinfected with HCV are more responsive to IFN therapy (5-6). Occult HBV infection, a condition in which HBV DNA and not HBsAg is detectable, may elevate the risk of hepatic diseases as well as the rate of non-response to conventional treatment of HCV (7). Due to shared routes of transmission, coinfection with HBV and HCV, particularly in endemic areas, is not uncommon (8). Dual infection is not limited to viral hepatitis C and B and clinical conditions may also vary. Senturk et al. concluded that HBV/HDV coinfection may have more serious implications compared to dual infection with HBV and HCV (9). Contradictory results have been reported regarding the extent to which HBV or HCV is dominant among patients with HBV and HCV coinfection; with more findings suggesting the suppression of HBV (10-14). Other in vitro findings have confirmed that HCV, through its core protein, brings about suppression of HBV replication (15-17). On the other hand, other studies showed that the dominance can change over the period of infection and some others reported the dominance of HBV (18-19). According to some limited studies, the treatment for HBV/HCV-coinfection is not straightforward and needs to be adjusted for individuals with different response rates (3, 5, 20). At the present time, no specific treatment guideline exists for this group of patients (21). A study by Liu in 2009 suggested that combination therapy with peginterferon alfa-2a and ribavirin is suitable for treating both HCV monoinfected and HBV/HCV coinfected individuals to the same extent (21). In another study, PEG-IFN-a2b and ribavirin was found to be effective in suppression of HCV among HBV/HCV-coinfected individuals (22). The aim of this study was to determine the prevalence rate of HCV infection among patients with HBV infection in the general population of Mashhad.

Methods

According to multi-stage cluster sampling method, from March 2010 to November 2011, 3198 people from the general population of Mashhad were screened for HBV infection and HBsAg detection was determined by ELISA, as described previously (23). The current study was ethically approved by Mashhad University of Medical Sciences. Following obtaining of informed consent, 10 milliliters blood sample was collected from each participant. Thirty four patients positive for HBsAg were then subjected for anti-HCV antibody screening by ELISA method (Delaware Biotech, USA).

Results

In the studied group, patients who were positive for HBsAg included 17 (50%) men and 17(50%) women with the mean age of 47.1±9.7 (range 19-63 years); none of them were found to be positive for HCV antibody by ELISA. Among 34 patients with HBV/HCV coinfection, one patient (2.94%), 26 patients (76.47%), and one patient (2.94%) were positive for HBeAg, HBeAb and HBc-IgM, respectively. HD-Ag was not detected in our infected patients. ELISA results for HBeAg, HBeAb and HBc-IgM in men and women were not statistically significant (P-value=0.999) (Table 1). Also one patient (2.94%) was positive for HBV using PCR method.

Discussion

Up to now, no large-scale studies have pointed out the global prevalence of HBV/HCV-coinfection. In addition to this fact, since occult HBV infection cannot be detected unless by sensitive molecular biology techniques, HBsAg screening, on its own, may not detect all cases of HBV (7, 24-25). Unlike this study which was performed in Iran and found no case of HBV/HCV coinfection, several studies in various regions of the world reported different prevalence rates. To mention some of them, In Taiwan, a prevalence rate of 3.4%, 12% and 18% was reported in 1991,
Table 1. ELISA results for HBeAg, HBeAb and HBc-IgM in HBsAg positive according to the gender.

<table>
<thead>
<tr>
<th>Gender</th>
<th>ELISA result</th>
<th>Positive</th>
<th>Number</th>
<th>Percent</th>
<th>Negative</th>
<th>Number</th>
<th>Percent</th>
<th>Total</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HBeAg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Positive</td>
<td>1</td>
<td>5.9%</td>
<td>16</td>
<td>94.1%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Positive</td>
<td>0</td>
<td>0.0%</td>
<td>17</td>
<td>100.0%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Positive</td>
<td>1</td>
<td>2.9%</td>
<td>33</td>
<td>97.1%</td>
<td>34</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statistical Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fisher's Exact Test p-Value=0.999</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>ELISA result</th>
<th>Positive</th>
<th>Number</th>
<th>Percent</th>
<th>Negative</th>
<th>Number</th>
<th>Percent</th>
<th>Total</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HBeAb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Positive</td>
<td>13</td>
<td>76.5%</td>
<td>4</td>
<td>23.5%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Positive</td>
<td>14</td>
<td>82.4%</td>
<td>3</td>
<td>17.6%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Positive</td>
<td>27</td>
<td>79.4%</td>
<td>7</td>
<td>20.6%</td>
<td>34</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statistical Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fisher's Exact Test p-Value=0.999</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>ELISA result</th>
<th>Positive</th>
<th>Number</th>
<th>Percent</th>
<th>Negative</th>
<th>Number</th>
<th>Percent</th>
<th>Total</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HBc-IgM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Positive</td>
<td>1</td>
<td>5.9%</td>
<td>16</td>
<td>94.1%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Positive</td>
<td>0</td>
<td>0.0%</td>
<td>17</td>
<td>100.0%</td>
<td>17</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Positive</td>
<td>1</td>
<td>2.9%</td>
<td>33</td>
<td>97.1%</td>
<td>34</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statistical Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fisher's Exact Test p-Value=0.999</td>
</tr>
</tbody>
</table>

1994 and 2001, respectively (26-28). Studies in Italy in 1991, 1999 and 2003 showed a prevalence rate of 15%, 14% and 7%, respectively (10, 29-30). Sato et al. and Ohkawa et al. reported a prevalence of 22% and 13%, respectively, in Japan in 1994 (11, 31). Two studies in China in 1994 and 1999 which included 193 and 103 individuals demonstrated the prevalence of 11% and 15%, respectively (32-33). Results from Spain, Thailand and India indicated the prevalence of 13%, 2.7% and 3%, respectively (34-36). Semnani et al study on 138 HBsAg-positive subjects in Iran, showed that 17 (12.3%) were positive for anti-HCV antibody (37). In another study in Iran, Cohan et al employed 207 chronic hepatitis C patients and evaluated the degree to which common HBsAg test is successful at detecting infection with HBV. Of the 207 patients, 23 (11.1%) were positive for HBV-DNA. However, only 6 of 23 were HBsAg positive (38). HBV/HCV coinfection
was observed in 21% of patients with injecting drug usage in Tehran, Iran (39). In another study in Tehran which was performed among patients with Human Immunodeficiency virus, the prevalence rate of 36.3% was observed for HBV/HCV coinfection (40). The authors’ previous studies among the population of Mashhad showed the HBsAg positivity of 0.53% (23) and the prevalence rate of 0.13% for Hepatitis C virus infection (41). In the current study, none of the patients positive for HBsAg were positive for anti-HCV. Detection of dual infection with HBV and HCV can contribute to its clinical management. Further studies with more sensitive molecular biology techniques to detect all cases of HBV are required to better understand the prevalence of HBV/HCV co-infection in the population of Mashhad, Iran.

References

13. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. Journal of clinical microbiology. 1998;36(7):2084-6.


24. Zhang YY, Hansson BG, Kuo LS, Widell A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology. 1993;17(4):538-44.


